Merck Reports the P-III (KEYLYNK-001) Study Data of Keytruda for Treating Advanced Epithelial Ovarian Cancer
Shots:
- Merck has reported results from the P-III (KEYLYNK-001) study assessing Keytruda + CT, followed by maintenance Lynparza (olaparib) with/without bevacizumab vs CT alone, in patients (n=1,367) with BRCA non-mutated advanced epithelial ovarian cancer
- Study achieved its 1EP, showing significant improvement in PFS with Keytruda regimen vs CT alone, but did not meet the 2EP of OS, leaving Keytruda's role in the broader population uncertain
- Safety profile of both the drugs aligned with the previous studies. The data will be highlighted at future conferences and shared with regulatory authorities
Ref: Merck | Image: Merck
Related News:- Merck Highlights the P-II (WaveLINE-007) Study Data of Zilovertamab Vedotin to Treat Diffuse Large B-Cell Lymphoma at ASH 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
